Guard Therapeutics

Executive Summary

Guard Therapeutics is a Swedish clinical-stage biotechnology company specializing in novel therapies for kidney diseases, leveraging its proprietary platform based on the endogenous protein alpha-1-microglobulin. The company's lead candidate targets acute kidney injury (AKI) and chronic kidney disease (CKD), addressing significant unmet medical needs with a unique mechanism of action. Listed on Nasdaq First North Growth Market Stockholm, Guard Therapeutics has demonstrated promising preclinical efficacy and safety, positioning itself for potential first-in-class therapies in nephrology.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 topline data readout for lead candidate in AKI60% success
• H2 2026Potential partnership or licensing deal for alpha-1-microglobulin platform40% success
• Q4 2026Initiation of Phase 1/2 trial for CKD indication70% success